Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Therapeutic Advances in BRAFV600E-mutant mCRC

3 Nov 2023Oncology

Connie TANG

Share

This content is sponsored. It is intended for healthcare professionals only.

// ONCOLOGY Last updated: | In: Article Keywords Prof Jayesh Desai Associate Director of Clinical Research Head, Early Drug Development, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia At a symposium co-organised by the Hong Kong Society of Clinical Oncology and Pierre Fabre,

PR-PIE-2022400-mCRC-Highlight

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026